FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026903046> ?p ?o ?g. }

• W3026903046 endingPage "4215" @default.
• W3026903046 startingPage "4206" @default.
• W3026903046 abstract "Abstract Purpose: PARP inhibitors (PARPi) are standard-of-care therapy for high-grade serous ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with olaparib (PARPi) at emergence of PARPi resistance. Patients and Methods: The proof-of-concept EVOLVE study (NCT02681237) assessed cediranib–olaparib combination therapy after progression on a PARPi. Women with HGSOC and radiographic evidence of disease progression were enrolled into one of three cohorts: platinum sensitive after PARPi; platinum resistant after PARPi; or progression on standard chemotherapy after progression on PARPi (exploratory cohort). Patients received olaparib tablets 300 mg twice daily with cediranib 20 mg once daily until progression or unacceptable toxicity. The coprimary endpoints were objective response rate (RECIST v1.1) and progression-free survival (PFS) at 16 weeks. Archival tissue (PARPi-naïve) and baseline biopsy (post-PARPi) samples were mandatory. Genomic mechanisms of resistance were assessed by whole-exome and RNA sequencing. Results: Among 34 heavily pretreated patients, objective responses were observed in 0 of 11 (0%) platinum-sensitive patients, 2 of 10 (20%) platinum-resistant patients, and 1 of 13 (8%) in the exploratory cohort. Sixteen-week PFS rates were 55%, 50%, and 39%, respectively. The most common grade 3 toxicities were diarrhea (12%) and anemia (9%). Acquired genomic alterations at PARPi progression were reversion mutations in BRCA1, BRCA2, or RAD51B (19%); CCNE1 amplification (16%); ABCB1 upregulation (15%); and SLFN11 downregulation (7%). Patients with reversion mutations in homologous recombination genes and/or ABCB1 upregulation had poor outcomes. Conclusions: This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis. In this setting, the activity of cediranib–olaparib varied according to the PARPi resistance mechanism." @default.
• W3026903046 created "2020-05-29" @default.
• W3026903046 creator A5004788266 @default.
• W3026903046 creator A5011411233 @default.
• W3026903046 creator A5015928554 @default.
• W3026903046 creator A5019722619 @default.
• W3026903046 creator A5021338846 @default.
• W3026903046 creator A5024148150 @default.
• W3026903046 creator A5028100343 @default.
• W3026903046 creator A5028785687 @default.
• W3026903046 creator A5038405310 @default.
• W3026903046 creator A5051302491 @default.
• W3026903046 creator A5061371368 @default.
• W3026903046 creator A5062783802 @default.
• W3026903046 creator A5072207500 @default.
• W3026903046 creator A5072712459 @default.
• W3026903046 creator A5077484404 @default.
• W3026903046 creator A5078365633 @default.
• W3026903046 creator A5086996122 @default.
• W3026903046 creator A5089583274 @default.
• W3026903046 creator A5091441287 @default.
• W3026903046 creator A5091553589 @default.
• W3026903046 date "2020-08-14" @default.
• W3026903046 modified "2023-10-13" @default.
• W3026903046 title "EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression" @default.
• W3026903046 cites W1781764024 @default.
• W3026903046 cites W1898580708 @default.
• W3026903046 cites W2065849886 @default.
• W3026903046 cites W2067117419 @default.
• W3026903046 cites W2102209369 @default.
• W3026903046 cites W2103386635 @default.
• W3026903046 cites W2103441770 @default.
• W3026903046 cites W2113836212 @default.
• W3026903046 cites W2123696077 @default.
• W3026903046 cites W2138601221 @default.
• W3026903046 cites W2151509048 @default.
• W3026903046 cites W2151876400 @default.
• W3026903046 cites W2155943701 @default.
• W3026903046 cites W2160466424 @default.
• W3026903046 cites W2169456326 @default.
• W3026903046 cites W2171892226 @default.
• W3026903046 cites W2171972386 @default.
• W3026903046 cites W2404952574 @default.
• W3026903046 cites W2406250479 @default.
• W3026903046 cites W2416275929 @default.
• W3026903046 cites W2438866487 @default.
• W3026903046 cites W2528228811 @default.
• W3026903046 cites W2528953057 @default.
• W3026903046 cites W2589382098 @default.
• W3026903046 cites W2623263876 @default.
• W3026903046 cites W2737389832 @default.
• W3026903046 cites W2754327139 @default.
• W3026903046 cites W2758959882 @default.
• W3026903046 cites W2765435739 @default.
• W3026903046 cites W2807649309 @default.
• W3026903046 cites W2887027058 @default.
• W3026903046 cites W2889646458 @default.
• W3026903046 cites W2892812402 @default.
• W3026903046 cites W2896250649 @default.
• W3026903046 cites W2897430921 @default.
• W3026903046 cites W2899159263 @default.
• W3026903046 cites W2900291138 @default.
• W3026903046 cites W2901506506 @default.
• W3026903046 cites W2902886329 @default.
• W3026903046 cites W2913578326 @default.
• W3026903046 cites W2924441988 @default.
• W3026903046 cites W2946425279 @default.
• W3026903046 cites W2968820602 @default.
• W3026903046 cites W2978670157 @default.
• W3026903046 cites W3031903430 @default.
• W3026903046 doi "https://doi.org/10.1158/1078-0432.ccr-19-4121" @default.
• W3026903046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32444417" @default.
• W3026903046 hasPublicationYear "2020" @default.
• W3026903046 type Work @default.
• W3026903046 sameAs 3026903046 @default.
• W3026903046 citedByCount "73" @default.
• W3026903046 countsByYear W30269030462020 @default.
• W3026903046 countsByYear W30269030462021 @default.
• W3026903046 countsByYear W30269030462022 @default.
• W3026903046 countsByYear W30269030462023 @default.
• W3026903046 crossrefType "journal-article" @default.
• W3026903046 hasAuthorship W3026903046A5004788266 @default.
• W3026903046 hasAuthorship W3026903046A5011411233 @default.
• W3026903046 hasAuthorship W3026903046A5015928554 @default.
• W3026903046 hasAuthorship W3026903046A5019722619 @default.
• W3026903046 hasAuthorship W3026903046A5021338846 @default.
• W3026903046 hasAuthorship W3026903046A5024148150 @default.
• W3026903046 hasAuthorship W3026903046A5028100343 @default.
• W3026903046 hasAuthorship W3026903046A5028785687 @default.
• W3026903046 hasAuthorship W3026903046A5038405310 @default.
• W3026903046 hasAuthorship W3026903046A5051302491 @default.
• W3026903046 hasAuthorship W3026903046A5061371368 @default.
• W3026903046 hasAuthorship W3026903046A5062783802 @default.
• W3026903046 hasAuthorship W3026903046A5072207500 @default.
• W3026903046 hasAuthorship W3026903046A5072712459 @default.
• W3026903046 hasAuthorship W3026903046A5077484404 @default.
• W3026903046 hasAuthorship W3026903046A5078365633 @default.
• W3026903046 hasAuthorship W3026903046A5086996122 @default.

• next